Capital International Investors Crispr Therapeutics Ag Transaction History

Capital International Investors

$557 Billion
Q2 2025

A detailed history of Capital International Investors transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Capital International Investors holds 5,593,747 shares of CRSP stock, worth $324 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

5,593,747

Previous 6,073,118 7.89%

Holding current value

$324 Million

Previous $207 Million 31.65%

% of portfolio

0.05%

Previous 0.04%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$31.27 - $48.64 $15 Million - $23.3 Million	-479,371 Reduced 7.89%	5,593,747 $272 Million
Q1 2025 May 12, 2025	SELL	$34.03 - $53.02 $90.9 Million - $142 Million	-2,670,405 Reduced 30.54%	6,073,118 $207 Million
Q4 2024 Feb 13, 2025	BUY	$38.65 - $55.15 $31.6 Million - $45 Million	816,789 Added 10.3%	8,743,523 $344 Million
Q3 2024 Nov 13, 2024	BUY	$44.62 - $62.75 $2.74 Million - $3.86 Million	61,481 Added 0.78%	7,926,734 $372 Million
Q2 2024 Aug 13, 2024	BUY	$51.17 - $68.18 $1.44 Million - $1.92 Million	28,179 Added 0.36%	7,865,253 $425 Million
Q1 2024 May 14, 2024	BUY	$60.67 - $89.12 $103 Million - $152 Million	1,702,624 Added 27.76%	7,837,074 $534 Million
Q4 2023 Feb 13, 2024	BUY	$38.62 - $72.18 $1.89 Million - $3.53 Million	48,938 Added 0.8%	6,134,450 $384 Million
Q3 2023 Nov 13, 2023	BUY	$45.39 - $59.0 $716,662 - $931,551	15,789 Added 0.26%	6,085,512 $276 Million
Q2 2023 Aug 11, 2023	BUY	$43.47 - $67.77 $2 Million - $3.12 Million	46,085 Added 0.77%	6,069,723 $341 Million
Q1 2023 May 15, 2023	BUY	$41.0 - $56.12 $27.4 Million - $37.5 Million	669,088 Added 12.5%	6,023,638 $272 Million
Q4 2022 Feb 14, 2023	BUY	$39.19 - $65.67 $475,453 - $796,708	12,132 Added 0.23%	5,354,550 $218 Million
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $41.5 Million - $56.8 Million	678,464 Added 14.55%	5,342,418 $349 Million
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $45.9 Million - $78.4 Million	1,061,802 Added 29.48%	4,663,954 $283 Million
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $584,664 - $871,006	10,992 Added 0.31%	3,602,152 $226 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $41.1 Million - $65.3 Million	-586,507 Reduced 14.04%	3,591,160 $272 Million
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $45.5 Million - $64.7 Million	-413,254 Reduced 9.0%	4,177,667 $468 Million
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $28 Million - $45 Million	-277,768 Reduced 5.71%	4,590,921 $743 Million
Q1 2021 May 14, 2021	SELL	$110.72 - $210.04 $283 Million - $537 Million	-2,558,027 Reduced 34.44%	4,868,689 $593 Million
Q4 2020 Feb 12, 2021	BUY	$79.67 - $173.23 $2.58 Million - $5.62 Million	32,442 Added 0.44%	7,426,716 $1.14 Billion
Q3 2020 Nov 13, 2020	BUY	$78.5 - $100.64 $537 Million - $688 Million	6,841,159 Added 1236.84%	7,394,274 $618 Million
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $6 Million - $11.1 Million	178,115 Added 47.5%	553,115 $23.5 Million
Q4 2019 Feb 18, 2020	BUY	$36.68 - $73.13 $8.69 Million - $17.3 Million	237,000 Added 171.74%	375,000 $22.8 Million
Q3 2018 Nov 14, 2018	BUY	$44.35 - $65.71 $6.12 Million - $9.07 Million	138,000 New	138,000 $6.12 Million

Others Institutions Holding CRSP

# of Institutions

531

Shares Held

68.7M

Call Options Held

3.67M

Put Options Held

2.25M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.51B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.

Account

Capital International Investors Crispr Therapeutics Ag Transaction History